Oral administration of a new HRI activator as a new strategy to improve high‐fat‐diet‐induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21

BACKGROUND AND PURPOSE: FGF21 has emerged as a therapeutic strategy for treating type 2 diabetes mellitus due to its antidiabetic effects, and this has led to the development of long‐acting analogues of FGF21. However, these compounds have some limitations, including a need to be administered by s.c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Pharmacol
Auteurs principaux: Zarei, Mohammad, Pujol, Eugènia, Quesada‐López, Tania, Villarroya, Francesc, Barroso, Emma, Vázquez, Santiago, Pizarro‐Delgado, Javier, Palomer, Xavier, Vázquez‐Carrera, Manuel
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555855/
https://ncbi.nlm.nih.gov/pubmed/30927369
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14678
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires